Merck
FDA Accepts NDA for Merck’s Once-Daily, Oral, 2-Drug Regimen for HIV-1 Treatment
The FDA accepted for review the New Drug Application for doravirine-islatravir, an investigational, once-daily, ...
JULY 10, 2025
ACIP Recommends Capvaxive for Certain Adults Ages 19 and Older
The ACIP unanimously voted to recommend Capvaxive to vaccinate certain adults ages 19 and older to protect against ...
JUNE 28, 2024
FDA Approves Capvaxive Pneumonia Vaccine
The FDA approved Capvaxive for adults to prevent against invasive pneumococcal disease and pneumonia caused ...
JUNE 20, 2024
Right Drug for the HABP and VABP Patient
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are among the most common and ...
AUGUST 23, 2023
Investigative Enzyme Inhibitor May Help Combat Antimicrobial Resistance
Initial data about MK-3402, an investigative metallo-beta-lactamase inhibitor being investigated by Merck, which ...
JUNE 17, 2023
New Indication for Prevymis to Prevent CMV in High-Risk Kidney Transplant Recipients
The FDA granted a new indication for letermovir for prophylaxis of CMV disease in high-risk adult kidney transplant ...
JUNE 6, 2023
A New Era for Managing Clostridioides difficile Infection
In the last decade, we have started to understand the critical components of the gut microbiome that prevent C. ...
APRIL 3, 2023
FDA Approves IM Administration of Merck’s MMRV Family of Vaccines
The FDA has approved the inclusion of intramuscular (IM) administration to the United States Product Insert for ...
MARCH 6, 2023
Prevymis Gets Priority Review for New Indication Decision
Merck is seeking two new indications for Prevymis against cytomegalovirus in transplant patients.
FEBRUARY 17, 2023
Oral COVID-19 Medications Gain Popularity, Despite Some Concerns
As oral antiviral medications for the treatment of COVID-19 become more widely accepted—and ...
OCTOBER 13, 2022
FDA Grants Expanded Indication for Vaxneuvance Vaccine
PCV15 is now indicated for active immunization in people 6 weeks and older to prevent invasive disease caused by ...
JUNE 22, 2022
Investigational 2-Drug HIV Regimen Appears Safe, Effective
Merck's islatravir is an investigational first-in-class nucleoside reverse transcriptase translocation inhibitor ...
SEPTEMBER 13, 2019
